Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well cabozantinib and temozolomide work in treating patients
with leiomyosarcoma or other soft tissue sarcoma that cannot be removed by surgery
(unresectable) or has spread to other places in the body (metastatic). Cabozantinib may stop
the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used
in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor
cells, either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Giving cabozantinib and temozolomide may work better than either one alone in
treating patients with leiomyosarcoma or other soft tissue sarcoma. Cabozantinib is an
investigational drug, which means that it has not been approved by the United States (US)
Food and Drug Administration (FDA) or any other regulatory agencies for sale or use by the
public for the indication under investigation in this study.
Phase:
Phase 2
Details
Lead Sponsor:
City of Hope Medical Center Northwestern University